Watch DYN. Know when insiders buy.
One email the day a filing lands. Free.
DYN
Dyne Therapeutics, Inc.
20.31
−3.97 −16.35%
USD · close Sep 8
A free account adds a watchlist, alerts when insiders, Congress or short sellers move on your tickers, and a morning brief. Sign up
Work order
48
WATCH · insiders 39, shorts 56
Insiders, 90 days
−$248K
net selling · 0 buys, 5 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $3.8BP/E —DIV YIELD —FCF YIELD -12.67%REV TTM —NET INCOME −$519.4MNET CASH $476.8M52W 12.37 – 26.78SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | — | — | — | −$181.7M | −$178.6M | — | -1.08 | −$130.3M | $1.5M | −$131.8M | Jul 29 |
| Q1 2026 · Mar 31 | — | — | — | −$125.3M | −$120.9M | — | -0.73 | −$144.9M | $221K | −$145.1M | Jul 29 |
| Q4 2025 · Dec 31derived | — | — | — | −$116.1M | −$112M | — | -0.73 | −$111.8M | $484K | −$112.3M | Mar 2 |
| Q3 2025 · Sep 30 | — | — | — | −$113.9M | −$108M | — | -0.76 | −$90.8M | $395K | −$91.2M | Nov 5 |
| Q2 2025 · Jun 30 | — | — | — | −$115.8M | −$110.9M | — | -0.97 | −$94.7M | $60K | −$94.8M | Jul 29 |
| Q1 2025 · Mar 31 | — | — | — | −$122.4M | −$115.4M | — | -1.05 | −$105.9M | $981K | −$106.9M | Jul 29 |
| Q4 2024 · Dec 31derived | — | — | — | −$97.1M | −$89.5M | — | -0.88 | −$84.3M | $1.1M | −$85.4M | Mar 2 |
| Q3 2024 · Sep 30 | — | — | — | −$105.6M | −$97.1M | — | -0.96 | −$74.6M | $253K | −$74.9M | Nov 5 |
| Q2 2024 · Jun 30 | — | — | — | −$72M | −$65.1M | — | -0.70 | −$54.9M | $857K | −$55.7M | Nov 5 |
| Q1 2024 · Mar 31 | — | — | — | −$69.2M | −$65.6M | — | -0.81 | −$78.5M | $191K | −$78.7M | Nov 5 |
| Q4 2023 · Dec 31derived | — | — | — | −$67.7M | −$66.6M | — | -1.09 | −$35M | $82K | −$35.1M | Mar 2 |
| Q3 2023 · Sep 30 | — | — | — | −$62.3M | −$60.2M | — | -0.99 | −$50.6M | $167K | −$50.8M | Nov 12 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | — | — | −$468.2M | −$446.2M | — | -3.47 | −$403.2M | $1.9M | −$405.1M | — | — |
| FY2024 · to Dec 31 | — | — | −$343.9M | −$317.4M | — | -3.37 | −$292.4M | $2.4M | −$294.7M | — | — |
| FY2023 · to Dec 31 | — | — | −$242.2M | −$235.9M | — | -3.95 | −$188.2M | $729K | −$188.9M | — | — |
| FY2022 · to Dec 31 | — | — | −$171M | −$168.1M | — | -3.23 | −$153.6M | $3.1M | −$156.7M | — | — |
| FY2021 · to Dec 31 | — | — | −$150M | −$149.3M | — | -2.93 | −$119.6M | $3.6M | −$123.2M | — | — |
| FY2020 · to Dec 31 | — | — | −$58.6M | −$59.4M | — | -4.13 | −$46.5M | $1.2M | −$47.7M | — | — |
Every number comes from Dyne Therapeutics, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.